To kick off Mental Health Awareness Month, Schrier shares his story on how genetic testing and the IDgenetix® test can help match genes to drugs to improve treatment outcomes
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company that improves health through innovative tests that guide patient care, today announced a collaboration with Camille Schrier , Miss America 2020, to promote the potential of genetic testing and the IDgenetix® test to help improve the treatment of mental health disorders. The Company recently added IDgenetix, a pharmacogenomic (PGx) test for mental health disorders, to its commercial testing portfolio.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220505006064/en/
Camille Schrier, Miss America 2020 and Doctor of Pharmacy candidate at Virginia Commonwealth University (Photo: Business Wire)
Schrier has long suffered from anxiety and depression, as well as a genetic condition that causes chronic pain. She’s been taking antidepressants for more than a decade, but results from an IDgenetix test showed the dose of her current medication could be improved; she is now working with her clinician to find the best course of action. “IDgenetix has given me new hope to alleviate what has been a lifelong struggle,” Schrier said.
Started by the organization Mental Health America in 1949, Mental Health Awareness Month is designed to help raise awareness of the importance of mental health and wellness in the United States. Yet rates of anxiety and depression continue to rise.1 To support this annual event and promote mental health education and awareness, Schrier will share her journey by describing changes in her medication based on the IDgenetix test and how those changes affected her symptoms and her life.
“This campaign aims to help patients with depression, anxiety, and other mental health issues improve their chances of getting a beneficial drug response,” Schrier continued. “IDgenetix is unique in that it is designed to take into account not only genetic variants, but also multiple drug interactions.”
In a randomized controlled trial, patients diagnosed with depression who were assessed with the IDgenetix test showed >2.5-fold improvement in remission rates compared to those whose genes were not tested with IDgenetix. The test is designed to identify genes shown to determine how quickly or slowly the body processes certain drugs. IDgenetix also assesses possible drug interactions, which are integrated into the bioinformatics analysis of the test. By using the IDgenetix test report, doctors may be able to more precisely tailor treatments to each patient, rather than relying on trial and error, potentially reducing the risk of side effects or ineffective treatments. .
“We are delighted that Camille has agreed to collaborate with Castle for the benefit of patients with mental disorders,” said Derek Maetzold, President and CEO of Castle Biosciences. “Camille’s personal story as a patient with depression and a future pharmacist makes her a powerful spokesperson. She will help us spread our message of hope to millions of patients who may be suffering from unresolved symptoms, while educating physicians who are turning to precision medicine to overcome trial and error and potentially improve the odds of a response. or remission.
IDgenetix is a pharmacogenomics (PGx) test for depression, anxiety, and other mental health disorders designed to analyze a patient’s genetic makeup to guide timely, evidence-based decisions about the optimal medication for each patient. IDgenetix is designed to provide important genetic information to clinicians to help guide their patients’ personalized treatment plans, with the potential to help patients achieve a faster therapeutic response and improve their chances of remission by identifying appropriate medications more effectively than standard of care. error approach and. IDgenetix provides drug-drug and drug-gene interactions and is backed by a published peer-reviewed randomized controlled trial that demonstrated clinical utility against standard of care when physicians used IDgenetix prior to prescribing a drug. IDgenetix is currently reimbursed by Medicare for the following eight mental health disorders: major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, panic disorder, obsessive-compulsive personality disorder, post-traumatic stress disorder, and brain deficit disorder. attention with hyperactivity.
To learn more, visit www.IDgenetix.com and join us on LinkedIn, Facebook, Twitter and Instagram.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The Company aims to transform disease management by putting people first: patients, clinicians, employees and investors.
Castle’s current portfolio includes tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for testing in other diseases of high clinical need, including its test in development to predict systemic therapeutic response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeqDecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeqTissueCypher and IDgenetix are registered trademarks of Castle Biosciences, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “sphere of security” created by these sections. These forward-looking statements include, but are not limited to, statements regarding: IDgenetix’s ability to enable physicians to more precisely tailor treatments to individual patients and reduce the risk of side effects or ineffective treatments by helping linking genes to drugs to improve treatment outcomes for mental health conditions; and the expected benefits of the partnership discussed in this press release contributing to awareness and education for patients and physicians experiencing unresolved symptoms and helping to improve the chances of response or remission for mental health issues. The words “may”, “may”, “will”, “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those contained in the forward-looking statements, including, without limitation: the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business; the results and conclusions of subsequent studies or trials may contradict the results and conclusions of prior studies or trials, including with respect to the IDgenetix test mentioned in this press release; actual application of our tests, including IDgenetix, may not provide the potential benefits contemplated in this press release; and the risks set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in our other filings with the SEC. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statements except as required by law.
1World Health Organization: https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression- worldwide; accessed May 4, 2022